Antisense Oligonucleotides Against Cpla2, Compositions and Uses Thereof
AssigneesMor Research Applications Ltd., Ben-Gurion University of the Negev Research and Development Authority
InventorRachel Levy
Life of this patent
Estimating the term…
Abstract
Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.
Claims44
An antisense oligonucleotide directed against the open reading frame (ORF) of the cytosolic phospholipase A2 (cPLA2) mRNA sequence, and functional analogs, derivatives or fragments thereof, wherein the complementarity of said antisense oligonucleotide is within the region between nucleotides 145 to 400 of said ORF, and wherein said antisense oligonucleotide is capable of inhibiting the expression of the cPLA2 protein.
An antisense oligonucleotide directed against the 5′ region of the open reading frame of the cytosolic phospholipase A2 (cPLA2) mRNA sequence, and functional analogs, derivatives or fragments thereof, wherein said antisense oligonucleotide has the sequence as denoted by any one of SEQ. ID. No. 1, SEQ. ID. No. 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ. ID No. 5, and SEQ. ID. No. 6.
The antisense oligonucleotide of any one of the preceding claims, optionally labeled with one of fluorescent, radioactive, metal particle, and any suitable labeling means.
The pharmaceutical composition of any one of the preceding claims, optionally further comprising buffers, additives, stabilizers, diluents and/or excipients.
Dependencies are inferred from the claim text.